Transthyretin and the brain re-visited: Is neuronal synthesis of transthyretin protective in Alzheimer’s disease?

Xinyi Li and Joel N Buxbaum*

Abstract
Since the mid-1990’s a trickle of publications from scattered independent laboratories have presented data suggesting that the systemic amyloid precursor transthyretin (TTR) could interact with the amyloidogenic β-amyloid (Aβ) peptide of Alzheimer’s disease (AD). The notion that one amyloid precursor could actually inhibit amyloid fibril formation by another seemed quite far-fetched. Further it seemed clear that within the CNS, TTR was only produced in choroid plexus epithelial cells, not in neurons. The most enthusiastic of the authors proclaimed that TTR sequestered Aβ in vivo resulting in a lowered TTR level in the cerebrospinal fluid (CSF) of AD patients and that the relationship was salutary. More circumspect investigators merely showed in vitro interaction between the two molecules. A single in vivo study in Caenorhabditis elegans suggested that wild type human TTR could suppress the abnormalities seen when Aβ was expressed in the muscle cells of the worm. Subsequent studies in human Aβ transgenic mice, including those from our laboratory, also suggested that the interaction reduced the Aβ deposition phenotype. We have reviewed the literature analyzing the relationship including recent data examining potential mechanisms that could explain the effect. We have proposed a model which is consistent with most of the published data and current notions of AD pathogenesis and can serve as a hypothesis which can be tested.

Keywords: Beta-amyloid precursor protein (AβPP, APP), Beta-amyloid (Aβ), Alzheimer’s disease (AD), Transthyretin (TTR), Amyloidosis, Protein homeostasis, Aggregation

Introduction
All amyloid fibrils are similar in appearance, displaying Congophilic, non-branching fibrils 7.5-10 nm in diameter. The twenty nine (thus far) identified human amyloid precursors [1] share no primary sequence and no common conformation although recent biophysical studies suggest the presence of conformationally/energetically similar repeat subunits which determine whether a given protein belongs to the “amylome” [2]. Further it has been suggested that while the precursors represent a variety of folded and unfolded native structures, a combination of primary structural features and level of expression determines the ordering of proteins along a proposed “edge of stability” under in vivo conditions, i.e. there are both qualitative and quantitative factors that influence whether a protein will aggregate in vivo [3,4]. The frequency of many of the amyloidoses increases with aging but their deposition appears to be independent, i.e. each has its own anatomically predisposed site and pattern [5]. Thus, while there are reported instances of mixed precursor deposition, they are relatively uncommon, e.g. [6-9]. Nonetheless the commonality of structure that leads precursor proteins to form fibrils suggests that interaction could occur, perhaps accelerating fibril formation. The example of transthyretin (TTR) and β-amyloid (Aβ) raises the question as to whether the effect may be, in truth, to reduce fibrillogenesis.

Wild type and mutant forms of TTR are the precursors in the systemic human diseases, Familial Amyloidotic Polyneuropathy (FAP), Familial Amyloidotic Cardiomyopathy (FAC) and Senile Systemic Amyloidosis (SSA) [10]. In contrast, Alzheimer’s disease (AD) is a localized amyloid disease of the brain. AD and the TTR
Amyloidoses share age dependence and are manifested as both autosomal dominant, mutation-related and sporadic (wild type protein associated) diseases. In the TTR amyloidoses the precursor is synthesized primarily by hepatocytes distant from the main sites of deposition in peripheral nerve and heart. However local synthesis and deposition can be seen in the eye, gut, kidney and choroid plexus. In AD the β-amyloid precursor protein (AβPP) is synthesized ubiquitously but deposition and tissue compromise are restricted to the brain and even more so to specific brain regions. The first association of TTR with AD was the observation that cerebrospinal fluid (CSF) could inhibit Aβ fibril formation in vitro [11]. TTR [12] was the third CSF protein found to interact with Aβ after apolipoprotein E (ApoE) [13] and ApoJ (or clusterin) [14]. It was hypothesized at that time that these three extracellular proteins could “sequester” Aβ, thereby preventing neuronal damage, although there was little evidence presented as to how or where such sequestration could take place. Perhaps “chaperone” in the sense of “protector” might have been a better term than “sequester”, but the oxymoronic phrase “pathologic chaperone” had already been utilized to describe the co-deposition of ApoE in AD plaques [15].

Results of the early experiments supporting the association and suggesting that the interaction could be beneficial were suspect because of reservations concerning methodology. Further, the notion that an in vivo systemic amyloid precursor could have a salutary effect on the course of another, albeit local, form of amyloidosis, derived from a different precursor, taking place in a different, relatively closed anatomic compartment seemed counterintuitive. Lastly the published evidence that TTR was not a neuronal protein, but synthesized in choroid plexus epithelium made it seem unlikely that it could have much to do with the primarily neuronal degenerative process produced by aggregation of a protein produced in/by neurons [16].

We will review the relevant published papers that have contributed to our current knowledge regarding the relationship between TTR and AD. We will try to point out the inconsistencies that have cast doubt on the pathogenetic importance of the connections and we will present hypotheses that have been proposed to account for the interaction.

Alzheimer’s Disease
The neuropathologic hallmarks of human AD include extracellular senile plaques consisting primarily of fibrils representing aggregated Aβ peptides, intracellular neurofibrillary tangles composed of hyperphosphorylated microtubule-binding tau protein [17-19], and synaptic and neuronal loss particularly in the hippocampus and cortex, the regions associated with cognition and memory (reviewed in [20]). In addition inflammation (reviewed in [21,22]), oxidative damage (reviewed in [23-25]) and reactive gliosis [26] are evident in AD brains.

The precise molecular mechanisms responsible for the pathology of AD are still unclear although there is no lack of reasonable models. Since the original isolation and identification of Aβ and AβPP, the weight of clinical and experimental evidence supports a major, if not primary role for Aβ in the development of AD (reviewed in [27-29]). Whether it is the ultimate source of the pathology is uncertain but the evidence for involvement of AβPP in AD pathogenesis is convincing.

AβPP processing pathways
AβPP is a 695-770 amino acid glycosylated membrane protein with a single hydrophobic transmembrane domain of 23 residues [30]. A large hydrophilic amino-ectodomain of AβPP is cleaved by α- or β-secretase to produce secreted AβPP fragments, sAPPα or sAPPβ, respectively [31] (see Figure 1). Alpha-secretase is a member of the ADAM (a disintegrin and metalloprotease) family of proteases anchored in the cell membrane [32-36], which includes ADAM9 [33], ADAM10 [35], ADAM17 (also known as tumour necrosis factor-α convertase, TACE) [37] and ADAM19 [36]. The sAPPα fragment appears to be involved in the development of the nervous system, promoting neurite outgrowth [38,39], synaptogenesis [40,41], enhancing memory formation [42], and providing neuro-protection against excitotoxic stimuli [43] and metabolic and oxidative insults [44] (for review see [45]).

Beta-secretase (BACE-1) is a predominantly β-site amyloid precursor protein-cleaving aspartyl-protease [46,47]. However the earlier notion that BACE-1 is the only β-secretase activity protease in vivo [48,49] has been challenged [50-52]. The BACE-1 cleavage product, sAPPβ, does not have the same neuroprotective properties as sAPPα. It has been recently shown that upon further cleavage, sAPPβ releases a 35 kDa amino terminal fragment (N-APP), representing amino acids 1-286 of AβPP, that behaves as a ligand for neuronal death receptor 6 (DR6) [53]. That molecule has been hypothesized to be involved in pruning of synapses during development of both central and peripheral neurons [53]. The investigators suggested that aberrant activation of the “death signal” could play a role in AD pathogenesis but there is no published direct evidence for such an effect in AD (Figure 1).

Alpha and β cleavages also yield small cytoplasmic carboxy-terminal fragments (CTF’s), CTF83 and CTF99, respectively. In the so-called non-amyloidogenic pathway, CTF83 is digested by γ-secretase, a complex with
presenilin 1 at its catalytic core [54] (for γ-secretase reviews see [55-59]), releasing the APP intracellular domain (AICD) which may contribute to the toxicity of AD [60] and the extracellular p3 element with as yet no known function (reviewed in [61,62]). In the amyloidogenic pathway, CTF99 is cleaved by γ-secretase resulting in AICD and small peptides called Aβ ranging from 38 to 43 amino acids. Aβ1-40 and Aβ1-42 are the dominant forms in senile plaques [63,64]. Aβ1-42 is more amyloidogenic and more prevalent in plaques than Aβ1-40 [64] but the latter is more abundantly secreted by cultured cells [65,66]. Aβ1-42 is generated in the endoplasmic reticulum/Golgi/intermediate compartment (ERGIC) [67,68], while Aβ1-40 is generated in trans-Golgi network (TGN) [68]. The endosomal/lysosomal system also plays a role in generating Aβ [69] (Figure 1).

**Clearance of Aβ**

The amyloidogenic peptides may be taken up by microglial and astrocytic endocytosis [70,71]; in the brain or by endothelial cells comprising the blood-brain barrier (BBB) [72]. They also form the neuropathologically diagnostic extracellular amorphous or fibrillar deposits (plaques). Some of the released peptides may enter the brain interstitial fluid (ISF) go to the CSF, then to the bloodstream, a pathway which may be responsible for 10%-15% of cerebral clearance of Aβ. The majority of clearance occurs via transport through the BBB [73].
Low-density lipoprotein receptor-related protein (LRP) regulates Aβ clearance by carrying the peptide from brain to blood via transportation across the BBB [73] with the assistance of two other transporter ligands, apoE and α2-macroglobulin (α2M) (reviewed in [74,75]). The receptor for advanced glycation end products (RAGE) is the influx receptor for Aβ [76,77].

Besides taking up soluble and fibrillar Aβ, microglia and astrocytes also secrete proteinases that degrade Aβ extracellularly [71,78]. Aβ can be degraded by a number of proteases including angiotensin converting enzyme (ACE) [79,80], Cathepsin B [81], endothelin converting enzymes (ECE) [82], glutamate carboxypeptidase II [83], matrix metalloproteinases (MMP-2/gelatinase A [84], MMP-9/gelatinase B [85,86]), plasmin [87,88], neprilysin (also known as neutral endopeptidase 24.11 (NEP) and enkephalinase) [89,90] and insulin degrading enzyme (IDE, insulysin) [78,91]. Deficiency of neprilysin [92,93] and IDE [94] caused increased cerebral accumulation of endogenous Aβ in transgenic models of AD in vivo. Moreover, overexpression of neprilysin [95,96] and IDE [96] reduced Aβ levels and plaque burden in similar transgenic mice. Lipidated ApoE enhanced degradation of Aβ by neprilysin [97].

Amyloid hypothesis and alternatives

With Aβ as its focus, the current version of the “amyloid hypothesis” as the etiology of Alzheimer’s disease proposes that “soluble oligomers” formed by Aβ are the toxic agents rather than monomers or fibrils. The extracellular oligomers are proposed to induce inflammatory responses, oxidative stress etc. and ultimately cause neuronal spine and synaptic loss through an as yet unknown mechanism [98-101].

There is abundant evidence favoring an Aβ-centric hypothesis. Patients with Down’s syndrome, caused by trisomy 21, thus carrying a third copy of the AβPP gene, uniformly develop AD-like pathology after age 40. The increased AβPP gene dose results in elevated Aβ level and early deposition of extracellular Aβ, neuritic plaques and neurofibrillary tangles [102-104]. In familial AD (FAD) mutations of presenilin 1 and 2 and AβPP genes cause early onset FAD with increased amounts of Aβ [105-108] or ratio of Aβ42/Aβ40 [109,110]. In an early onset form of AD, the so-called Swedish double mutation (K670N/M671L), cleavage by β-secretase is enhanced with subsequent increased production of total Aβ [111].

Transgenic mouse AD models have been created using genes encoding mutant forms of presenilin and AβPP that have been identified in autosomal dominant forms of human AD. To some extent they all reproduce AD phenotypes, more closely resembling the early stages of the human disease than the globally symptomatic condition (see reviews [112-114]). The AβPP models seem to require multiple copies of the mutant gene, creating a molecular environment more analogous to that in Down’s syndrome than in sporadic human AD. It is not certain that the organismal response to multiple copies of a gene encoding a mutant protein is absolutely analogous to the disease produced by an aggregated fragment from two copies of a normal AβPP gene. Nonetheless the molecular events and the pathologic sequelae are similar.

In human AD patients, the severity of pathology correlates best with the concentration of soluble Aβ in the brain, not with that of the insoluble plaques, the morphologic hallmark of AD [115,116]. In brain-slices, dimers and trimers of Aβ are synaptic toxins and oligomers inhibit long term potentiation [117-120]. Recently, it has been suggested that oligomeric Aβ1-42 binds to PrPc and inhibits synaptic plasticity [121], however that observation has not been confirmed in all laboratories [122].

Other functional studies have indicated that the degree of dementia in AD is more highly correlated with the presence of neurofibrillary tangles than amyloid plaques [123,124]. However those studies antedated the analyses of soluble Aβ. Patients with mild cognitive impairment (MCI) who develop AD have lower levels of Aβ1-42, higher total tau (T-tau) protein, and tau phosphorylated at threonine 181 (P-tau181) in CSF than those who do not [125,126]. In CSF of AD patients, the decreased Aβ1-42 and increased tau levels appear to be good biomarkers for some purposes [127-129].

In cell culture, in vitro synthesized Aβ oligomers are toxic to a variety of cells [130]. When added to primary cultured murine neurons, the oligomers cause synaptic loss, calcium imbalance [131], disruption of mitochondria [132], with subsequent oxidative stress similar to that seen in brains of AD patients [133]. However most in vitro toxicity studies used synthetic Aβ peptides and required higher (μM) concentrations than those likely to be encountered in vivo. In addition the aggregation-prone nature of Aβ has made it difficult to identify the precise conformations of the toxic species. Despite these correlations, the relationship between Aβ cytotoxicity in tissue culture and the mechanism of neuronal loss in AD is still uncertain.

Hypotheses alternative to the amyloid cascade include a primary effect of ApoE on metabolism [134], membrane dysfunction caused by Aβ dimers [135], primary axonal transport dysfunction [136,137], oxidative stress related to aging, primary mitochondrial dysfunction or cerebrovascular disease [24] and a primary presenilin defect. These challenges to the amyloid cascade hypothesis have persisted (see reviews [138-142]), particularly since clinical trials of agents which targeted clearance of
amyloid plaques or inhibition of γ-secretase have failed [143]. Nonetheless the hypothesis remains dominant with the failures being interpreted as being related to either inadequate specificity (in the case of γ-secretase inhibitors, resulting in off-target toxicity), unresponsive stage of disease, or neurovascular inflammation (as with the anti-Aβ antibodies) [144].

**Transthyretin (TTR)**

Unlike the circumstance in AD where AβPP is produced and processed in neurons and Aβ aggregates form primarily in the CNS, TTR, a 55 kDa homotetrameric protein, causes disease by depositing as aggregates primarily at a distance from the major site of synthesis. The circulating protein is produced predominantly in the liver, which rarely displays evidence of aggregation or dysfunction. The TTR amyloidoses are prototypical systemic gain of toxic function disorders. The toxic species is comprised of aggregates formed from monomers which misfold after they dissociate from the homotetramer [145]. The most common form of TTR aggregation disease is senile systemic amyloidosis (SSA), caused by wild type TTR protein deposits in the heart, which increases in prevalence in the aged, with frequencies as high as 10-20% in the 9th and 10th decades, perhaps even higher in older groups [146,147]. Mutant TTR protein deposits in peripheral and autonomic nerves and heart are responsible for disease in familial amyloidotic polyneuropathy (FAP), and familial amyloidotic cardiomyopathy (FAC). More than 80 mutants have been reported to be responsible for autosomal dominant deposition disease [148]. CNS deposition has not been noted in FAP except in the choroid plexus and leptomeninges [148]. Mutant TTR protein deposits in peripheral and autonomic nerves and heart are responsible for disease in familial amyloidotic polyneuropathy (FAP), and familial amyloidotic cardiomyopathy (FAC). More than 80 mutants have been reported to be responsible for autosomal dominant deposition disease [148]. CNS deposition has not been noted in FAP except in the choroid plexus and leptomeninges with rare unstable mutants (TTR’s D18G, A25T, L12P) and in some cases of individuals carrying more common mutations, e.g. TTR V30M, which are primary sites of TTR synthesis [10]. The carriers of those mutations have a characteristic clinical CNS presentation, even though there does not appear to be actual neuronal involvement by the aggregates [149,150].

TTR is a thyroid hormone (thyroxine (T4)) carrier and the only known plasma retinol (vitamin A) transporter, binding to retinol binding protein (RBP) charged with retinol. The binding sites for its normal ligands, T4 and RBP have been well defined [151-153]. Surprisingly, mice with their endogenous ttr gene silenced have no apparent functional phenotype with respect to either thyroid function or vitamin A metabolism as long as vitamin A is supplied in the diet [154-156]. They have been shown to have a behavioral abnormality, the nature of which is currently under active investigation [157,158] and have been reported by one laboratory to have a neuropeptide Y phenotype with obesity and hyperphagia [159]. They also appear to have a defect in peripheral nerve repair in response to injury and an abnormality in the proportion of proliferating to apoptotic cells in the supraventricular zone in the embryonic brain [160,161].

In clinical situations in humans the serum TTR level (0.08-0.45 mg/ml) is used as a marker for malnutrition as well as inflammation, decreasing in both clinical settings [162]. Its serum level is decreased in patients with some tumors [163,164], although it is not clear whether the decrease is related to an inflammatory response or is an intrinsic property of the tumors.

TTR is encoded by a single copy of gene located on chromosome 18 in human and chromosome 4 in mouse. The gene contains four exons with the first exon encoding the leader sequence (reviewed in [10]). The gene is expressed in liver, kidney, pancreas, choroid plexus [165], retinal epithelium, leptomeningeal epithelium [166]. Despite the frequency of cardiac TTR deposition there does not appear to be either TTR gene transcription or TTR protein synthesis in the heart (Buxbaum unpublished). Several groups have shown material reactive with anti-TTR antibodies present in brain parenchyma indicating that the TTR mRNA is effectively translated [167-169]. However those observations could also be explained by neuronal endocytosis of TTR synthesized in choroid plexus epithelium [170,171]. More recent studies, using microarray analysis of RNA from carefully dissected regions of brains from multiple animals showed strain and regional variation in ttr transcription in different areas of the brain parenchyma [172]. These results differ from those seen in earlier work, using primarily Northern blotting, which suggested that the choroid plexus was the only site of ttr transcription in the brain and that the apparent neuronal expression was a function of contamination with choroid plexus or leptomeningeal epithelium [16,173-175]. The most recent results suggest that normally there is a very low level of neuronal TTR synthesis [169,176] with substantial increase in particular pathologic states [169].

**Transthyretin in human AD**

Early immunopathologic studies, based on the premise that TTR might be the amyloid precursor in AD, gave conflicting results with respect to the presence of TTR in plaques in human AD brains [177,178]. More recent analyses found TTR co-localized in hippocampal plaques and vessels of AD patients [167,168]. Anti-TTR serum stained the majority of neuronal bodies in AD brains but only 10% of neurons in age-matched nondemented controls [169]. The latter finding may be responsible for the many reports of TTR synthesis only in the choroid plexus in the normal brain since the TTR signal from the choroid plexus, ependyma and leptomeninges is much stronger than that from normal neurons [16,179].
TTR, ApoE and ApoJ (clusterin) are major Aβ-binding proteins in human CSF [12-14]. The mean CSF TTR level has been reported to be decreased in several series of AD patients [180-184]. However not all investigators have found this to be true [185]. The significance of the decrease is not clear. It has been proposed, on the basis of the decrease, that TTR sequesters Aβ but no site of sequestration has been identified. It is also possible that the CSF TTR concentration may be determined in part by neuronal TTR synthesis [169], particularly in AD (as well as choroid plexus production) and that the observed reduction is related to neuronal loss. Also plausible is the possibility that patients with AD have a genetic or acquired low CSF TTR level independent of the CSF TTR concentration. It is inferred, as a second hypothesis, that the interaction between Aβ/TTR was also noted in human kidneys [191], and in the muscle of a single patient with inclusion body myositis [192]. However its significance in these circumstances is unclear since the subjects did not have clinical AD.

It was hypothesized that TTR could inhibit Aβ related toxicity by sequestering of Aβ thus preventing Aβ aggregation and fibril formation based on the observation that first identified TTR as an Aβ-binding protein in CSF [167]. In subsequent studies of the capacity of a series of recombinant mutant TTR’s to inhibit Aβ fibril formation at neutral pH in vitro was analyzed. The investigators found that the amount of Congo red binding material formed over a 24-36 hour period was reduced in the presence of many of the recombinant TTR’s (at a 5:1 molar ratio of Aβ:TTR). However, the experiments suffered from the lack of non-TTR e.g. albumin, controls and the use of a relative measure of inhibitory capacity that was never quantified in terms of protein concentration. In addition the nature of the Aβ1-42 when it was added to the assay was not precisely defined. Given current knowledge regarding the propensity of Aβ to aggregate on standing, it is not clear from the publications whether the different TTR’s were actually seeing the same Aβ conformers. Nonetheless in retrospect the observation that TTR bound Aβ and inhibited fibril formation was correct, although the detailed results regarding the relative capacities of different variants are less likely to be valid. The hypothesis itself was attractive since TTR is abundant in Human CSF (5-20 µg/ml or 0.1-0.36 µM) and serum (174-420 µg/ml or 3-7 µM) [12,193]; while Aβ concentration in CSF is relatively low (3 nM or less) [194,195]. However it inferred, as a second hypothesis, that the interaction would be responsible for lowering the CSF TTR concentration.

**Transthyretin in AD worm and mouse models**

The initial in vitro studies were followed by the intriguing report that in C. elegans, wild type human TTR co-expressed with Aβ in body wall muscle cells under control of the same (unc 54) promoter rescued a phenotype of defective locomotion seen in animals expressing only Aβ [196]. The significance of those data was not clear since no follow up studies were reported in the same system. However with the development of transgenic mouse models of AD it became possible to examine the phenomenon in a more disease-relevant experimental system.

In the transgenic mouse AD model Tg2576 in which the human APP Swedish mutation is expressed under the control of a hamster prion promoter and is associated with plaques, dystrophic neurites, vascular involvement and gliosis, analyses of transcription showed up-regulation of ttr. TTR protein was immunohistochemically detected in neurons in the hippocampus and cerebral cortex, although neuronal-specific ttr transcripts were not assessed [171,197]. TTR immunoreactivity was seen in the same areas as the Aβ-staining plaques. Furthermore, injection of anti-TTR antibodies into one ventricle increased Aβ deposition on the injected side relative to that seen in the contralateral cerebral hemisphere [168], suggesting that the reduction of functionally available TTR caused the increased AD-like pathology.

In later studies in the APP23 mouse model (Swedish mutation controlled by the Thy 1 promoter), hippocampal and cortical regions of brains from 15-month old mice showed neuronal staining for TTR and co-staining for Aβ and TTR in the deposits. The blood vessels were also Aβ and TTR positive [158]. Crossing the APP23 mice with a mouse strain over-expressing wild type human TTR under the control of its own promoter (APP23/hTTR+) normalized cognitive function and spatial learning as well as diminishing the neuropathologic changes and the amounts of Aβ deposited in the animals bearing both constructs [158]. Moreover, APP23/mtttr-/- animals showed Aβ deposition in the hippocampus and/or cortex 3 months earlier than in the presence of the ttr gene [158]. In animals sacrificed at 5.5 months
of age the frequency and amount of Aβ staining and extractable Aβ in the brains of the APP23/mtrr+/+ were greater than in the APP23/mtrr−/− mice [158]. Another AD transgenic mouse model, the ceAPPswe/PS1ΔE9 mouse, hemizygous for a silenced ttr allele, also showed earlier deposition than controls but not as early as in the homozygous knockouts in the APP23 mice [198], suggesting a gene dose effect.

Results of experiments examining the effects of silencing the ttr gene on other models of AD have not been uniform. In contrast to the results suggesting a salutary effect of TTR in the Tg2576 AD model [171], other investigators reported that total and vascular Aβ burdens in pooled 13-20 month-old Tg2576/TTR+/− mouse brains were significantly increased compared to Tg2576/ TTR−/− mice [199]. The investigators saw no difference in the age of onset and progression between the two strains of mice. However those conclusions were based on examining only two mice from each group per month, which is probably not sufficient to be certain of the observations regarding the pace of development of disease reported in the APP23 mice. In addition homozygous Tg2576/TTR−/+ control mice were not included in the study so there was no comparison between ttr−/+ and ttr−/− animals. Similar studies were performed in TgCRND8 mice, a more aggressive AD model of Aβ deposition in which plaques develop as early as 3 months. The magnitude of spatial memory deficits and Aβ plaque burden were not different in the hippocampi of 6-month-old TgCRND8/TTR+/−, TgCRND8/TTR−/− and TgCRND8/TTR−/+ mice [200]. In that model it might have been too late at 4 and 6 months of age to observe significant changes in the rate of development of disease due to the deletion of the ttr gene as suggested by the APP23 and ceAPPswe/PS1ΔE9 experiments.

The variability in the results of the gene silencing experiments may be due to differences in the mouse strains studied. Alternatively, since it is clear that mice with two intact copies of the ttr gene still develop AD-like pathology, and there is considerable variation in the degree of pathology and behavioral abnormality seen from mouse to mouse in the same strain, it is difficult to get significant results without using relatively large numbers of animals of the same gender, precisely matched for age if one is trying to determine the pace of development of disease, rather than degree of pathology at the endpoint, which may be independent of the presence or absence of TTR. It is possible that examining the knockouts is observing the loss of a physiologic inhibitor/modulator of the pathogenetic process and more subject to mouse to mouse variation, while the over-expressed wild type hTTR transgene experiment is more analogous to a pharmacologic manipulation in which the agent is provided in sufficient quantities to overcome individual host differences. It might be useful to cross the hTTR over-expressing mice with animals bearing other AD mutants to be certain that the results seen in the APP23 strain were not peculiar to that strain combination.

Transthyretin and Aβ in vitro interaction

In contrast to the results from in vivo mouse studies, results from in vitro experiments analyzing the interaction between TTR and Aβ are more consistent, particularly in recent years when we have come to understand how to control the behavior of pro-amyloidogenic proteins in solution in vitro [201].

Schwarzman et al studied 47 recombinant TTR variants (see above). Most (except G42 and P55) bound to Aβ and inhibited Aβ aggregation in vitro [202]. But the interpretation of those experiments is subject to some reservations with respect to the experimental methodology (vide supra). Wild type human TTR binds to all forms of soluble Aβ, monomer, oligomer and fibrils [158,203-205]. TTR binds to Aβ better at 37°C than 25°C [158], binds to Aβ aggregates better than Aβ monomer [158,205,206], and Aβ1-42 better than Aβ1-40 [158]. The binding is highly dependent on the quaternary structure of TTR [206]. It has been suggested that human monomeric TTR binds Aβ better than the TTR tetramer. On the basis of tandem mass spectrometry analysis of a glutaraldehyde cross-linked TTR-Aβ fragment, the Aβ binding site appeared to be located in the A strand, in the inner β-sheet and EF helix of TTR [206]. These putative sites must be confirmed independently, using a different methodology. They do not correspond or encompass the sites proposed earlier based on structural modeling [12]. If the sites are correct then mutations in the potential binding residues should reduce affinity or abrogate binding completely.

The stoichiometry and the binding affinity of the Aβ-TTR interaction have been difficult to establish, perhaps because of the tendency of Aβ to aggregate, so that its molecular mass at any moment of the interaction is probably heterogeneous. Using a tryptophan fluorescence quenching method, Ks was estimated at 2300 M−1 for TTR and Aβ soluble species [205]. The authors noted that the Ks could be underestimated by several orders of magnitude because the Aβ monomer molecular weight was used in the estimation and it is likely that much of the bound Aβ was heterogeneously oligomeric. Using a competition binding method with radioiodinated Aβ1-42 (presumably a stronger binder than Aβ1-40) as the ligand the Kd was estimated to be 28 nM [203]. However there is still lack of independent confirmation of this relatively strong interaction constant. In contrast to other laboratories the same investigators...
concluded that the binding between TTR and various Aβ species is similar.

Nonetheless, it is now apparent, as originally suggested by Goldgaber and his colleague [12,202], that the interaction between TTR and Aβ interferes with Aβ aggregation in vitro. Using a variety of methods at least four other laboratories have now shown that TTR inhibits Aβ fibril formation [158,203-205]. While it appears from some assays that TTR inhibits oligomer formation in others the mechanism of inhibition of fibril formation may be mediated via suppression of large aggregate formation (Li and Buxbaum, unpublished). Two groups have clearly shown that monomeric TTR suppresses Aβ fibril formation better than TTR tetramer (Li and Buxbaum, unpublished) [206]. The interaction between TTR and Aβ species is apparently beneficial to cultured cells under Aβ stress. TTR prevented accumulation of the Aβ in cultured vascular smooth muscle cells [207]. In the human neuroblastoma cell line SK-N-BE, TTR inhibited ultrastructural changes characteristic of apoptosis [204]. Pre-incubation of Aβ with TTR also suppressed caspase-3 activation in the undifferentiated human neuroblastoma SH-SY5Y cell line [203] and the cytotoxicity induced by Aβ oligomers on SH-SY5Y cells differentiated by retinoic acid treatment [169]. Moreover, TTR also inhibited cytotoxicity and the induction of reactive oxygen species (ROS) by Aβ species in cultured embryonic mouse neurons [169].

Is the beneficial effect of transthyretin direct?

While TTR binding to Aβ appears to be well documented it is not clear how such binding impacts on AD in vivo. The notion of “sequestration” has been floated from the very beginning however, where or how the Aβ is being “sequestered” is not apparent (see Figure 2 for hypothesis). It has also been suggested that TTR is a “cryptic protease” and cleaves Aβ [208], with subsequent disaggregation of the fibrils [203]. The data supporting this hypothesis have not been confirmed by other laboratories, either with respect to disaggregation or proteolysis under physiologic conditions. The concentration of recombinant TTR (13.6 μM) used to show cleavage of Aβ [208] is almost twice the level found in the serum and 30 times higher than the concentration of TTR in CSF [12,193]. Since the concentration of TTR in the brain has not been determined these results have to be interpreted carefully.

If the soluble Aβ oligomers or fibrils are the neurotoxic elements in AD patients or mouse models, the protective property of TTR can be a simple function of inhibiting aggregation and fibril formation by binding Aβ aggregates thus reducing their toxicity, as has been shown in vitro. TTR-Aβ complexes have been co-immunoprecipitated from the cerebral cortices of APP23 mice as well as some human AD brains using anti-TTR sera, although the precise conformer of the bound Aβ has not been established [169] (Figure 2).

In the APP23 AD mice over-expressing human TTR the amounts of SDS and formic acid extractable Aβ species were markedly reduced [158]. Thus, in this model the suggestion that given its amyloidogenic property, TTR may bind to Aβ and form large insoluble aggregates, thus protecting neurons from the toxicity induced by soluble oligomeric Aβ species has no experimental support. It is also possible that TTR may bind to AβPP as well inhibiting the cleavage of the AβPP by blocking at or close to α-, β-, or γ-secretase docking sites, thus reducing the amount of Aβ either by facilitating the non-amyloidogenic pathway (by helping α-secretase docking) or by inhibiting the amyloidogenic pathway (preventing β- or γ-secretase docking) [169]. This has been proposed to account for the salutary effect of the Br2 transgene in a transgenic AD model [209]. It is also possible that TTR binds to the secretases or both the secretases and AβPP (fragments/full-length) and blocks Aβ production. This is another possible explanation for the markedly decreased Aβ1-40/1-42 content in the presence of AβPP in the cortex of the hTTR over-expressing APP23 mice [169] (Figure 2).

Since the evidence indicates that TTR can bind many forms of Aβ it is also possible that TTR exerts its salutary effect on AD, particularly when it is over-expressed in the APP23 mice, by enhancing the hypothesized “plasma sink” by which Aβ-binding molecules in the circulation shift the equilibrium of newly generated Aβ from the brain, where the aggregates may be cytotoxic to the peripheral circulation, where they can be degraded. This has been proposed as an explanation for the effects of anti-Aβ antibodies, gelsolin and the ganglioside GM1 [210,211]. If that is the case it should be possible to isolate TTR-Aβ complexes from the serum of the human TTR over-expressing APP23 mice.

Is the beneficial effect of transthyretin indirect?

Despite the evidence supporting a direct interaction between TTR and Aβ-related peptides, the TTR effect might be indirect. As an amyloidosis precursor, TTR could activate the unfolded protein (UPR), and other proteostatic responses thus inducing chaperone transcription, or activating stress related pathways, thus changing the protein homeostasis network to be more efficient in coping with Aβ aggregation [212]. If this is the case, one would expect to find benefits from comparable over-expression of other amyloid precursor proteins. Wild type cystatin C and Bri2, other proteins in which mutations produce CNS amyloid deposition in humans, also inhibit Aβ fibril formation [213-216] (Table 1). Gelsolin, another human amyloid precursor
TTR inhibition of Ab aggregation (fibril formation) was reported by many groups [12,158,169,203-205] and current evidence suggested that the binding is mediated by association of monomeric TTR to Ab. It is also possible that TTR facilitates Ab degradation directly [208] or indirectly, transports of Ab from CNS into serum (plasma sink hypothesis) [12,202]. TTR may also inhibit Ab production by inhibition of γ-secretase cleavage [169].

Figure 2 Proposed mechanisms of TTR inhibition of Ab toxicity. TTR inhibition of Ab aggregation (fibril formation) was reported by many groups [12,158,169,203-205] and current evidence suggested that the binding is mediated by association of monomeric TTR to Ab. It is also possible that TTR facilitates Ab degradation directly [208] or indirectly, transports of Ab from CNS into serum (plasma sink hypothesis) [12,202]. TTR may also inhibit Ab production by inhibition of γ-secretase cleavage [169].
Table 1 Do Amyloid precursors “chaperone” Aβ?

| Protein        | Transgene suppresses | Knock-out accelerates | Cytotoxic inhibition | In vitro interaction | In Human AD brains |
|----------------|----------------------|-----------------------|---------------------|----------------------|--------------------|
| Transthyretin  | +                    | +                     | +                   | +                    | +                  |
| Brt2           | +                    | N.D.                  | N.D.                | +                    | +                  |
| Cystatin C     | +                    | N.D.                  | N.D.                | +                    | +                  |
| Gelsolin       | +*                   | N.D.                  | N.D.                | +                    | +                  |
| Neuroserpin    | **                   | N.D.                  | +                   | +                    | +                  |

N.D., Not Determined.

*Gelsolin only expressed in livers of transgenic animals.

**Neuroserpin experiments have only been done in transgenic drosophila.

binds Aβ [217] and ameliorates a transgenic AD model even when only expressed peripherally, a phenomenon more likely to reflect a “plasma sink” effect [218]. However each of these proteins binds Aβ directly and their effects cannot be attributed exclusively to stimulation of protein homeostatic mechanisms.

Others have argued that the TTR effect in AD models depends upon its function as an RBP binding protein. Increased TTR could increase the amount of available retinoic acid, thus enhancing neuronal maintenance. Similarly the accelerating effect of the TTR knockout could depend on a relative lack of retinoids in the CNS which amplifies the toxic effect of Aβ. Retinoic acid inhibitors have been shown to compromise neuronal function in older rodents and retinoic acid has been found to enhance performance [219,220]. Thus it would be useful to determine if expressing a human AD gene on an RBP knockout background in the presence and absence of TTR would reveal a different phenotype from that seen when the APP23 construct is expressed in the absence of TTR alone. There are also suggestions that TTR may also be involved in AD through a vascular mechanism. In such a scenario TTR would cleave apolipoprotein A-I (ApoA-I), a constituent of HDL resulting in reduced cholesterol efflux and increased formation of amyloid fibrils [221].

Given the multiple functions of TTR (reviewed in [222]), it also possible that TTR enhances mechanisms that specifically degrade Aβ, or that it plays a currently unknown role in the maintenance of critical neuronal functions.

Do Alzheimer’s peptides regulate neuronal transthyretin expression?

If TTR expression plays an important role in neuronal protection from Aβ aggregation or processing or in the normal function of AβPP, it would seem appropriate for its expression to be regulated by the system involved in the generation of Aβ or its related peptides. In hippocampal slices from Tg2576 AD mice TTR mRNA and protein were increased compared to WT mice [158,168,171]. The same was true in isolated cortex and hippocampus of the APP23 mice. We can also infer that the same is true in human AD since there is little neuronal staining for TTR in non-demented human brains and extensive staining brains from AD patients as reported anecdotally by Goldgaber and Johnson and systematically examined in our laboratory (see above). Since primary cultured neurons derived from 14-16d embryonic mice of the same genotypes show markedly increased expression of the TTR gene, it is safe to say that the increased staining is due to increased synthesis rather than uptake of choroid plexus synthesized TTR [169].

It had previously been suggested that sAPPα might increase TTR transcription, although at that time TTR mRNA had not been demonstrated in neurons [223]. In more recent studies it has been reported that the AICD fragment regulates transcription of other genes through activating Fe65 and the chromatin-remodeling factor Tip60 [224-227]. The genes regulated by AICD include neprilysin, the neutral endopeptidase with Aβ-degrading activity (vide supra) [225]; lipoprotein receptor LRP1 which is related to cholesterol metabolism and Aβ transport [228]; EGF receptor, whose promoter is bound by AICD and negatively regulated [229] etc. Most recently it has been suggested that the TTR and Klotho genes are specific downstream targets of sAPPβ [230]. TTR and Klotho expression are decreased in loss-of-function states but increased in gain-of-function states using transcriptional profiling [230] (Figure 1).

When mice are exposed to environmental “enrichment”, both the steady-state levels of Aβ peptides and Aβ deposition in brains of APPswe/PS1ΔE9 are significantly reduced, and ttr is one of the genes up-regulated [231]. Similarly administration of Gingko biloba and a number of unsaturated fatty acids to rodents have been reported to increase TTR mRNA abundance in cortical neurons as measured by microarray analysis [232-234]. Some of these compounds have had favorable effects in transgenic models of human AD [235,236]. However large studies of at least one of these in human AD patients have failed to show any benefit [237]. Perhaps this is just an example of “too little too late” rather than a conceptual error.
Summary: Transthyretin, aging and Alzheimer’s disease
Over-expression of human TTR suppresses the AD phenotype in a well validated model of human AD. Silencing the endogenous ttr gene appears to accelerate the disease but those results are less consistent. The majority of cortical and hippocampal neurons in human AD brains contain TTR protein as do the neurons in several murine AD models. The increased neuronal TTR is the result of increased transcription. In vitro interaction between recombinant TTR and synthetic Aβ has been demonstrated in multiple laboratories with the interaction reducing both fibril formation and Aβ-induced cytotoxicity in tissue culture. The interaction has now been shown to occur in vivo in both a murine model and in some human AD brains. Further it appears that TTR transcription may be directly influenced by the Aβ precursor. Thus wherever Aβ peptides are produced, i.e. intracellularly in neurons or secreted into the cerebral interstitial space, TTR is available, either on the basis of neuronal (intracellular) or choroid plexus production and secretion. If, as suggested by the in vitro studies, the TTR monomer is critical for binding intracellular Aβ, it is likely that newly synthesized peptide rather than dissociated tetramer is the source. Hence we would expect to find Aβ1-40/42 and TTR monomer in the same cellular compartment.

In the face of these data suggesting a role for TTR in suppressing the molecular events responsible for clinical AD, one must conclude that with time the amount of pathogenic Aβ peptide production exceeds the neuron’s capacity to neutralize it. This neutralizing capacity may be represented by the conventional protein homeostasis network (including the unfolded protein response, heat shock induced chaperones and their co-chaperones, the proteasome ubiquitin system and autophagic responses) [212]. It now appears that in this setting TTR may also comprise part of that network. There are considerable data suggesting that these mechanisms decline with aging. A relative deficiency of any of them may render the normal processes that deal with Aβ or its aggregates unable to compensate for a constant (or increased) aggregate load thus initiating disease. Such a scenario could certainly account for the findings in the over-production models of AD, whether it also applies in sporadic disease is a subject of speculation and further investigation. For the moment any such studies cannot ignore the role of TTR since hippocampal and cortical neurons from human AD and mouse AD model brains seem to increase its production.

Epilogue: Is transthyretin the only one?
Aβ amyloid formation, like all amyloidogenesis involves homotypic interactions that result in aggregation with subsequent toxic oligomer and fibril formation. Intracellular aggregation is suppressed by heterotypic interactions between the amyloidogenic precursors and elements of the chaperone system, allowing refolding or transport in the soluble state to either the secretory pathway or to the cellular degradative machinery. In the vast neuropathologic literature describing AD, a number of molecules have been found co-localized in the Aβ deposits. Similarly in the hundreds of publications utilizing the murine AβPP transgenic mice as AD models, there are reports of many manipulations that enhance or diminish the AD phenotype. We have presented a detailed analysis of the evidence suggesting that wild type TTR, a systemic amyloid precursor, can suppress Aβ aggregation in vitro and in vivo and ameliorate its pathologic effects in a well-validated transgenic mouse model of human AD. In the AD model literature we noted that reports indicating that wild type forms of other proteins rendered amyloidogenic by autosomal dominant mutations, e.g. Bri2 [215], cystatin C [213,214], gelsolin [217,218,238], and perhaps neuroserpin [239] (mutations result in non-amyloid neuropathologic aggregation), seem to be over-represented as a class. They appear to have the capacity to interact with Aβ and in some instances suppress the AD phenotypes in transgenic mouse models (see Table 1). It is possible that the same structural features that predispose these proteins to undergo the homotypic interactions that result in aggregation when affected by a particular structural change as a consequence of mutation, allow the wild type conformers to interact heterotypically to prevent aggregation of similarly susceptible client proteins, in this case Aβ. Whether the phenomenon represents therapeutically exploitable physiology remains to be seen.

Acknowledgements
The author’s work cited in this review was supported by NIH grant AG R01 030027 (JNB). NIH AG18440, AGS131, AG22074, AG11385, AG10435, NS057096 (Eliezer Masliah); WM Keck Foundation (JNB; XL)

Authors’ contributions
XL and JNB wrote the manuscript. Both authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 17 September 2011 Accepted: 23 November 2011 Published: 23 November 2011

References
1. Sipe JD, Benson MD, Buxbaum JN, Ikeda S, Merlini G, Saraiva MJ, Westermark P: Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid 2010, 17:101-104.
2. Goldschmidt L, Teng PK, Reik R, Eisenberg D: Identifying the amylophilic, proteins capable of forming amyloid-like fibrils. Proc Natl Acad Sci USA 2010, 107:3487-3492.
Apolipoprotein E: a pathological chaperone

7. Brancaccio D, Ghiggeri GM, Braidotti P, Garberi A, Gallieni M, Bellotti V,
6. Bergstrom J, Murphy C, Eulitz M, Weiss DT, Westermark GT, Solomon A,
11. Wisniewski T, Castano E, Ghiso J, Frangione B:
12. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ,
14. Ghiso J, Matsubara E, Koudinov A, Choi-Miura NH, Tomita M, Wisniewski T,
15. Wright JF, Calkins E, Breen WJ, Stolte G, Schultz RT: Relationship of
amyloid to aging. Review of the literature and systematic study of 83
patients derived from a general hospital population. Medicine 1969,
48:39-60.

Bergstrom J, Murphy C, Weiss DT, Westermark GT, Solomon A,

Frangione B: Codeposition of apolipoprotein A-I and transthyretin in
senile systemic (ATTR) amyloidosis. Biochem Biophys Res Commun 2001,
285:903-908.

8. de Souza MW, Vital C, Octler D, Fernandes R, Pougier-Abadie J, Carles D,
Saraiva MJ: Apolipoprotein AI and transthyretin as components of
amyloid fibrils in a kindred with apoaI Leu178His amyloidosis. Am J Pathol
2000, 156:1911-1917.

9. Takahashi K, Hoshi Y, Kawanoto H, Gondo T, Ishihara T, Isobe T:
Ultrastructural evidence for colocalization of kappa light chain-
and beta-2-microglobulin-derived amyloids using double labelling immunogold
electron microscopy. Virchows Arch 1996, 429:383-388.

10. Buxbaum JD: Transthyretin and the Transthyretin Amyloidoses. In Protein
Misfolding, Aggregate, and Conformational Diseases. Edited by: Uversky VN,
Fink A. Santa Cruz, California: Springer; 2007:259-283.

11. Wiessnieski T, Castano E, Ghiso J, Frangione B: Cerebrospinal fluid inhibits
Alzheimer beta-amyloid fibril formation in vitro. Ann Neurol 1993,
34:631-633.

12. Schwarzman AL, Gregori L, Vitek MP, Lyubski S, Strittmatter WJ, Enghilde JJ,
Bihan R, Silverman J, Wessgaber KH, Coyle PK: Transthyretin sequesters
amyloid beta protein and prevents amyloid formation. Proc Natl Acad Sci
USA 1994, 91:8386-8372.

13. Strittmatter WJ, Weisgaber KH, Huang DY, Dong LM, Salvesen GS, Pericak-
Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD: Binding of
human apolipoprotein E to synthetic amyloid beta peptide: isomorph-
specific implications for late-onset Alzheimer disease. Proc Natl
Acad Sci USA 1993, 90:8098-8102.

14. Ghiso J, Matsuura E, Koudinov A, Choi-Miura NH, Tomita M, Wisnieski T,
Frangione B: The cerebrospinal-fluid soluble form of Alzheimer’s amyloid beta
is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the
complement membrane-attack complex. Biochem J 1993, 293(Pt 1):1-12.

15. Wisnieski T, Frangione B: Apolipoprotein E: a pathological chaperone
protein in patients with cerebral and systemic amyloid. Neurosci Lett
1992, 135:235-238.

16. Sousa JC, Cardoso I, Marques F, Saraiva MJ, Palha JA: Transthyretin and
Alzheimer’s disease: where in the brain? Neurobiol Aging 2007,
28:713-718.

17. Kosik KS, Joachim CL, Selkoe DJ: Microtubule-associated protein tau (tau)
is a major antigenic component of paired helical filaments in Alzheimer
disease. Proc Natl Acad Sci USA 1986, 83:4044-4048.

18. Goedert M, Spillantini MG, Crowther RA: Alpha-synuclein as a Parkinson’s
disease protein. Nature 1997, 384:439-440.

19. Ihara Y, Nukina N, Miura R, Ogawa Y: Phosphorylated Tau protein is
integrated into paired helical filaments in Alzheimer’s disease. J Biochem
(Tokyo) 1986, 99:1807-1810.

20. Nollen K, de Leon MJ, Zetterberg H: Alzheimer’s disease: Lancet 2006,
368:387-403.

21. Akiyama H, Barger S, Barnum S, Bradt B, Barger J, Cole GM, Cooper NR,
Eikelenboom P, Emmerling M, Fiebich BL, et al: Inflammation and
Alzheimer’s disease. Neurobiol Aging 2005, 26:533-421..

22. Wyss-Coray T: Inflammation in Alzheimer disease: driving force,
bystander or key component? Trends Neurosci 2006, 29:1005-1015.

23. Christen Y: Oxidative stress and Alzheimer disease. Am J Clin Nutr 2000,
71:621-629.

24. Markesbery WR: Oxidative stress hypothesis in Alzheimer’s disease. Free
Radic Biol Med 1997, 23:154-147.

25. Sayre LM, Perry G, Smith MA: Oxidative stress and neurotoxicity. Chem Res
Toxicol 2007, 21:172-188.

26. Canning DR, McKeon RJ, DeWitt DA, Perry G, Wujek JR, Frederickson RCA,
Silver J. [Beta]-Amyloid of Alzheimer’s disease induces reactive gliosis
that inhibits axonal outgrowth. Exp Neurol 1993, 124:289-298.

27. LaFerla FM, Green KN, Oddo S: Intracellular amyloid [beta] in Alzheimer’s
disease. Nat Rev Neurosci 2007, 8:499-509.

28. Querfurth HW, LaFerla FM: Mechanisms of disease Alzheimer’s disease. N
Engl J Med 2010, 362:329-344.

29. Gandy S: The role of cerebral amyloid beta accumulation in common
forms of Alzheimer disease. J Clin Invest 2005, 115:1211-1219.

30. Ihara Y, Nukina N, Miura R, Ogawara M: Relationship of
Oxidative stress hypothesis in Alzheimer disease. Neurobiol Aging 1994,
15:27765-27767.

31. Jin LW, Ninomiya H, Roch J-M, Schubert D, Masliah E, Otero DA, Saitoh T:
Peptides containing the RERMS sequence of amyloid beta/A4 protein
precursor bind cell surface and promote neurite extension. J Neurosci
1994, 14:5461-5470.

32. Mattson MP: Secreted forms of beta-amyloid precursor protein modulate
dendrite outgrowth and calcium responses to glutamate in cultured
embryonic hippocampal neurons. J Neurosci 1994, 14:659-650.

33. Mucke L, Masliah E, Johnson WB, Ruppe MD, Aford M, Rockenstein EM,
Fors-Petter S, Pietropaolo M, Mallory M, Abraham CR: Synaptotrophic
effects of human amyloid beta protein precursors in the cortex of
transgenic mice. Brain Res 1994, 666:151-167.

34. Rock JM, Masliah E, Rock-Levecq AC, Sundmo MP, Otero DA, Veinbergs I,
Saitoh T: Increase of synaptic density and memory retention by a
peptide representing the trophic domain of the amyloid beta/A4 protein
precursor. Proc Natl Acad Sci USA 1994, 91:7450-7454.

35. Meziane H, Dodart JC, Mathis C, Little S, Clemens J, Paul SM, Ungere D:
Memory-enhancing effects of secreted forms of the beta-amyloid
precursor protein in normal and amnestic mice. Proc Natl Acad Sci USA 1998,
95:12683-12688.

36. Mattson MP, Cheng B, Culwell AV, Esch FS, Liederberg I, Rydel RE: Evidence
for excitoprotective and intraneuronal calcium-regulating roles for
secreted forms of the beta-amyloid precursor protein. Neurosci 1993,
10:243-254.

37. Goodman Y, Mattson MP: Secreted forms of beta-amyloid precursor protein
protect hippocampal neurons against amyloid beta-peptide-induced
oxidative injury. Exp Neurol 1994, 128:1-12.

38. Mattson MP: Cellular actions of beta-amyloid precursor protein and its
soluble and fibrilligenic derivatives. Physiol Rev 1997, 77:1081-1132.
of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. *Science*, 1999, 286:735-741.

47. Sinha S, Anderson JP, Barbour R, Basi GS, Caccavelli R, Davis D, Doan M, Doye HF, Frigon N, Hong J, et al. Purification and cloning of amyloid precursor protein (beta)-secretase from human brain. Nature 1999, 402:537-540.

48. Cai H, Wang Y, McCarthy D, Wen H, Allopp D, Roberts GW, Masters CL, Dotti CG, Unisicker K, et al. Distinct sites of intracellular production for Alzheimer’s disease A beta 40/42 amyloid peptides. *Nat Med* 1997, 3:1016-1020.

49. Koo EH, Squazzo SL. Evidence that production and release of amyloid beta-protein involves the endocytic pathway. *J Biol Chem* 1994, 269:17386-17389.

50. Zhang J, Gong Y, Au XM, et al. RAGE mediates amyloid-beta peptide uptake by neurons: implications for the pathology of Alzheimer’s disease. *J Biol Chem* 1998, 273:32730-32738.

51. De Strooper B. Alzheimer’s disease. Closing in on gamma-secretase. *Proc Natl Acad Sci USA* 2000, 97:12471-12474.

52. Hook V, Yu L, Aschmies S, Kirksey Y, Gonzales C, Xu J, et al. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is up-regulated by an ACE inhibitor. *J Biol Chem* 2001, 276:37644-37650.

53. Mueller-Steiner S, Zhou Y, Arai H, Roberson ED, Sun B, Chen J, Wang X, Yu G, Esposto L, Buckle M, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: Implications for Alzheimer’s disease. *Neuron* 2006, 51:703-714.

54. Eckman EA, Watson M, Marlow L, Sambamurti K, Eckman CB. Alzheimer’s disease beta-amyloid peptide is increased in mice deficient in endothelin-converting enzyme. *J Biol Chem* 2003, 278:20811-20814.

55. Kim MJ, Chae SS, Koh YH, Lee SK, Jo SA. GLUTAMATE CARBOXYPEPTIDASE II: a novel enzyme that degrades Alzheimer amyloid beta peptide (A beta) and retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. *J Neurochem* 2001, 77:4763-4768.

56. van de Braak WW, van den Berg A, Bannink AJ, van den Bosch F, Groeneveld JA, et al. The many roads to perdition. *Neuron* 2004, 43:605-608.

57. Mackic JB, Stinli M, McComb JG, Calero M, Ghiso J, Kim KS, Yan SD, Stern D, Schmidt MW, Frangione B, et al. Human blood-brain barrier receptors for Alzheimer’s amyloid-beta 1-40. Asymmetrical binding, endocytosis, and transcytosis at the apical side of brain microvascular endothelial cell monolayer. *J Clin Invest* 1998, 102:734-743.

58. Deane R, Du YS, Sumbarmayak RN, Laffue B, Jovanovic I, Sugi H, Yousif W, Al-Asheh A, Rosner MR, Madden LS, Lin C, Yu J, et al. Antiamyloidogenic and neuroprotective functions of cathepsin B: Implications for Alzheimer’s disease. *Neuron* 2006, 51:703-714.
Three-dimensional structure of the transthyretin-retinol-binding protein complex. Clin Chem Lab Med 2002, 40:1229-1236.

Andrea TA, Cavallen RR, Goldfine ID, Jorgensen EC. Binding of thyroid hormones and analogues to the human plasma protein prealbumin. Biochemistry 1980, 19:55-63.

Ruz A. The interaction of thyroxine with human plasma prealbumin and with the prealbumin-retinol-binding protein complex. J Biol Chem 1969, 244:3230-3237.

Episkopou V, Maeda S, Nishiguchi S, Shimada K, Gaitanaris GA, Gottesman ME, Robertson EJ. Disruption of the transthyretin gene results in mice with depressed levels of plasma retinol and thyroid-hormone. Proc Natl Acad Sci USA 1993, 90:2375-2379.

Palha JA, Hays MT, Monreal de EG, Episkopou V, Gottessman ME, Saraiva MJ. Transthyretin is not essential for thyroxine to reach the brain and other tissues in transthyretin-null mice. Am J Physiol 1997, 272:E465-493.

Weis S, Episkopou V, Pantedosi R, Maeda S, Shimada K, Gottessman ME, Bluner WS. Studies on the metabolism of retinol and retinol-binding protein in transthyretin-deficient mice produced by homologous recombination. J Biol Chem 1995, 270:866-870.

Sousa JC, Grandela C, Fernandez-Ruiz J, de Miguel R, de Sousa L, Magalhaes AI, Saraiva MJ, Sousa N, Palha JA. Transthyretin is involved in depression-like behaviour and exploratory activity. J Neurochem 2004, 88:1052-1058.

Buxbaum JN, Ye Z, Reisch N, Friske L, Levy C, Dav P, Golde T, Masliah E, Roberts AR, Bartfai T. Transthyretin protects Alzheimer’s mice from the behavioral and biochemical effects of A beta toxicity. Proc Natl Acad Sci USA 2005, 102:2681-2686.

Nunes AF, Saraiva MJ, Sousa MM. Transthyretin knockouts are a new mouse model for increased neuropeptide Y. FASEB J 2006, 20:166-186.

Fleming CE, Saraiva MJ, Sousa MM. Transthyretin enhances nerve regeneration. J Neurochem 2007, 103:831-839.

Richardson SJ, Lenkei GF, Alfama G, Hassani Z, Demeneix BA. Cell division and apoptosis in the adult neural stem cell niche are differentially affected in transthyretin null mice. Neurosci Lett 2007, 421:234-238.

Myron Johnson A. Clinical indications for plasma protein assays: transthyretin (prealbumin) in inflammation and malnutrition. International Federation of Clinical Chemistry and Laboratory Medicine (IFCC); IFCC Scientific Division Committee on Plasma Proteins (C-PP). Clin Chem Lab Med 2007, 45:419-426.

Kozak KR, Su F, Whitelegge JP, Faul K, Reddy S, Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 2005, 5:4895-4906.

Liu L, Liu J, Dai S, Wang X, Wu S, Wang J, Huang L, Xiao X, He D. Reduced transthyretin expression in sera of lung cancer. Cancer Sci 2007, 98:1617-1624.

Herbert J, Wilcox JH, Pham KT, Ferreau RT Jr, Zeviani M, Dwork A, Soprano DR, Makover A, Goodman DS, Zimmerman EA, et al. Transthyretin: A choroid plexus-specific transport protein in human brain: The 1986 S. Weir Mitchell Award. Neurology 1986, 36:3000.

Gertz RK, Kennedy BG, Mangoi NJ. Transthyretin localization in cultured and native human retinal pigment epithelium. Exp Eye Res 1999, 68:629-636.

Schwarzman AL, Goldgaber D. Interaction of transthyretin with amyloid beta-protein: binding and inhibition of amyloid formation. Ciba Found Symp 1996, 199:146-160.

Stein TD, Anders NJ, Dedicari C, Chen SL, Mattson MP, Johnson JA. Neutralization of transthyretin reverses the neuroprotective effects of secreted amyloid precursor protein (APP) in APP(Sw) mice resulting in tau phosphorylation and loss of hippocampal neurons: Support for the amyloid hypothesis. J Neurosci 2004, 24:7707-7717.

Li X, Masliah E, Reisch N, Buxbaum JN. Neuronal production of transthyretin in human and murine Alzheimer’s disease: is it protective? J Neurosci 2011, 31:12483-12490.

Carro E, Trejo JL, Gerber A, Torrado J, Metzger F, Torres-Alemán I. Therapeutic actions of insulin-like growth factor I on APP/P52 mice with severe brain amyloidosis. Neurobiol Aging 2006, 27:1250-1257.

Stein TD, Johnson JA. Lack of neurodegeneration in transgenic mice overexpressing mutant amyloid precursor protein is associated with increased levels of transthyretin and the activation of cell survival pathways. J Neurosci 2002, 22:7380-7388.

Hovatta I, Schadt EE, Liliger O, Schork NJ, Lockhart DJ, Barlow C, Zapala MA, Broide DS. DNA variation and brain region-specific expression.
profiles exhibit different relationships between inbred mouse strains: implications for eQTL mapping studies. Genome Biol 2007, 8:R25.

173. Dickson PW, Aldred AR, Marley PD, Bannister D, Schreiber G: Rat choroid plexus specializes in the synthesis and the secretion of transthyretin (prealbumin). Regulation of transthyretin synthesis in choroid plexus is independent from that in liver. J Biol Chem 1986, 261:3475-3478.

174. Murakami T, Ohswa Y, Sunada Y: The transthyretin gene is expressed in human and rodent dorsal root ganglia. Neurosci Lett 2008, 436:333-339.

175. Souza MM, Saraiva MJ: Transthyretin is not expressed by dorsal root ganglia cells. Exp Neurol 2008, 214:362-365.

176. Murakami T, Ohswa Y, Zhenghua L, Yamamura Ki, Sunada Y: The transthyretin gene is expressed in Schwann cells of peripheral nerves. Brain Res 2010, 1348:222-225.

177. Eikelenboom P, Stam FC: An immunohistochemical study on cerebral vascular and senile plaque amyloid in Alzheimer’s disease. Vochova Arch B Cell Pathol Incl Mol Pathol 1984, 47:17-25.

178. Shirahama T, Skinner M, Westermark P, Rubinow A, Cohen AS, Brun A, Li and Buxbaum: Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer disease. Neurol Res 2009, 16:399-397.

179. Ng L, Bernard A, Lau C, Overly CC, Dong HW, Kuan C, Pathak S, Sunlink SM, Dang C, Rohland JW, et al: An anatomic gene expression atlas of the adult mouse kidney. Nat Neurosci 2009, 12:352-362.

180. Serot JM, Christmann D, Dubost T, Couturier M: Transthyretin concentration in cerebrospinal fluid from Alzheimer disease patients. J Neuro Neurosurg Psychiatry 1997, 63:506-508.

181. Rissoin H: Reduced prealbumin (transthyretin) in CSF of severely demented patients with Alzheimer’s disease. Acta Neurol Scand 1988, 78:455-459.

182. Hansson SF, Andreasson U, Wall M, Skog I, Andreassen N, Wallin A, Zetterberg H, Blennow K: Reduced levels of amyloid-beta-binding proteins in cerebrospinal fluid from Alzheimer disease patients. J Alzheimers Dis 2009, 16:153-160.

183. Schultz K, Nilsson K, Nielsen JE, Lindquist SG, Hjermind LE, Andersen BB, Wallin A, Nilsson C, Petersen A: Transthyretin as a potential CSF biomarker for Alzheimer’s disease and dementia with Lewy bodies: effects of treatment with cholinesterase inhibitors. Eur J Neurol 2010, 17:456-460.

184. Cuenco KT, Friedland R, Baldwin CT, Guo J, Vandarajan B, Lunetta KL, Cupples LA, Green RC, Decarli C, Farrer LA: Association of TTR polymorphisms with hippocampal atrophy in Alzheimer disease families. JAMA 2008, 299:1112-1119.

185. Mazzu-Kolecka Bcdae, Frackowiak J, Wisniewski HM: Expression of human beta-amyloid peptide in transgenic mouse model of Alzheimer’s disease (TgCRND8). Neurodegener Dis 2010, 7:86-95.

186. Teplow DB: Preparation of amyloid beta-protein for structural and functional studies. Methods Enzymol 2006, 413:20-33.

187.社会实践。 Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta fibrillogenesis and toxicity. FEBS Lett 2008, 582:936-942.

188. Gutta S, Valli MB, Galeazzi R, Fattoretti P, Corder EH, Galeazzi L: Transthyretin inhibition of amyloid beta aggregation and toxicity. Clin Biochem 2005, 38:1112-1119.

189. Liu L, Murphy RM: Kinetics of inhibition of amyloid-beta aggregation by transthyretin. Biochemistry (Moscow) 2006, 45:15702-15709.

190. Du J, Murphy RM: Characterization of the interaction of beta-amyloid with transthyretin monomers and tetramers. Biochemistry (Moscow) 2010, 49:8276-8289.

191. Mazzu-Kolecka Bcdae, Frackowiak J, Wisniewski HM: Apolipoproteins E3 and E4 induce, and transthyretin prevents accumulation of the Alzheimers’s (beta)-amyloid peptide in cultured vascular smooth muscle cells. Brain Res 1995, 698:217-222.

192. Costa R, Ferreira-da-Silva F, Saraiva MJ, Cardoso I: Transthyretin binding to A-Beta peptide - Impact on A-Beta fibrillogenesis and toxicity. J Neurosci 2008, 28:936-942.

193. Matsuda S, Giliberto L, Matsuda Y, Davies P, McGowan E, Pickford F, Ghiso J, Frangione B, D’Adamo L: The familial dementia BR2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. J Biol Chem 2005, 280:28912-28916.

194. Matsuda Y, Saito M, LaFonclos J, Saito M, Gaynor K, Olm V, Wang L, Gavy E, Lu Y, Shriatani C, et al: Novel therapeutic approach for the treatment of Alzheimer’s disease by peripheral administration of agents with an affinity to beta-amyloid. J Neurosci 2003, 23:29-33.

195. Deane R, Bell RD, Sagare A, Zlokovic BV: Clearance of amyloid-beta peptide across the blood-brain barrier: implication for therapies in Alzheimer’s disease. CNS Neural Disord Drug Targets 2009, 8:16-30.

196. Balch WE, Miorinio RT, Dillin A, Kelly JW: Adapting proteostasis for disease intervention. Science 2008, 319:916-919.

197. Mi W, Pavlik M, Sastre M, Jung SS, Radivoy DS, Klein AM, Sommer J, Schmidt SD, Nixon RA, Mathews PM, et al: Cystatin C inhibits amyloid-beta deposition in Alzheimer’s disease mouse models. Nat Genet 2007, 39:1440-1444.

198. Kanner SA, Herzic MC, Coomaraswamy J, Kliger E, Senelica ML, Winkler DT, Stauflben Ml, Levy E, Grubb A, Jucker M: Cystatin C modulates cerebral beta-amyloidosis. Nat Genet 2007, 39:1437-1439.
Prevention of age-related spatial memory deficits in a transgenic mouse

Halver JE, Puskas LG:

Effects of dietary omega-3 polyunsaturated fatty acids from fish oil results in increased amyloidogenicity.

Ray I, Chauhan A, Wegiel J, Chauhan VPS:

Vincent R, Frangione B, Rostagno A, Mead S, Revesz T, Plant G, Ghiso J:

Vidal R, Frangiene B, Restagno A, Mead S, Revesz T, Plant G, Ghiso J: A stop-codon mutation in the BBI gene associated with familial British dementia. Nature 1999, 399:776-781.

Schultz PG, Gohil K:

von Rotz RC, Kohli BM, Bosset J, Meier M, Suzuki T, Nitsch RM, Konietzko U:

von Rotz RC, Kohli BM, Bosset J, Meier M, Suzuki T, Nitsch RM, Konietzko U: Transthyretin: a key gene involved in the prevention of dementia: a randomized controlled trial. JAMA 2008, 300:2253-2262.

Wang R, Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L, Cao X, Südhof TC:

Yao J, Li H, Wang B, Wang Z, Guo Q, Tabuchi K, Hammer RE, Südhof TC, Zheng H: Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Proc Natl Acad Sci USA 2010, 107:17362-17367.

Zhang YW, Wang R, Liu Q, Zhang H, Liao FF, Xu H: Presenilin-1/γ-secretase-dependent processing of β-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA 2007, 104:10613-10618.

Zhang YW, Wang R, Liu Q, Zhang H, Liao FF, Xu H: Presenilin-1/γ-secretase-dependent processing of β-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA 2007, 104:10613-10618.

Zhao Y, Wang R, Liu Q, Zhang H, Liao FF, Xu H: Presenilin-1/γ-secretase-dependent processing of β-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA 2007, 104:10613-10618.

Zhou X, Wang R, Liu Q, Zhang H, Liao FF, Xu H: Presenilin-1/γ-secretase-dependent processing of β-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA 2007, 104:10613-10618.

Zhou X, Wang R, Liu Q, Zhang H, Liao FF, Xu H: Presenilin-1/γ-secretase-dependent processing of β-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA 2007, 104:10613-10618.

Zhou X, Wang R, Liu Q, Zhang H, Liao FF, Xu H: Presenilin-1/γ-secretase-dependent processing of β-amyloid precursor protein regulates EGF receptor expression. Proc Natl Acad Sci USA 2007, 104:10613-10618.